CD19 chimeric antigen receptor T2 cell therapy - Guangdong Zhaotai InVivo
Alternative Names: CD19-CAR T cell therapy - Guangdong Zhaotai InVivoLatest Information Update: 28 Apr 2019
At a glance
- Originator Guangdong Zhaotai InVivo Biomedicine
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Leukaemia(In children, Second-line therapy or greater, In adults) in China (Parenteral, Infusion)
- 01 Jan 2016 Phase-I clinical trials in Leukaemia (In children, In adults, Second line therapy or greater) in China (Parenteral, Infusion) (NCT02822326)